MJ Biotech Wholly Owned Subsidiary, New England Biotech And Joint Venture Partner Genesis Botanical Research Secures CBD Extraction Facility Location

CHEYENNE, WY / ACCESSWIRE / January 19, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to announce that it's partner Genesis Botanical Research, has secured the location for the first of their CBD extraction facilities. The facility, once constructed, will be owned by MJTV's wholly owned subsidiary New England Biotech, Inc.

This first CBD extraction facility will be located in Sagadahoc County in the Mid-Coast-Central Maine area. The facility is expected to be operational in the Third or Fourth Quarter of 2021. It is the plan of the company to have a second CBD facility operational within 12 months after the opening of the first CBD facility or sooner.

Steps have already been taken by Genesis Botanical Research in anticipation of the completion of the first facility, to secure high quality reliable sources of Hemp for the CBD extraction. Within just a few short months of opening, the facility expects to be at or near full capacity and will be generating revenue before the end of 2021.

For additional information please contact us at [email protected].

Safe Harbor Statement: Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. MJ Biotech Inc. does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated status of such statements. Therefore, in no case whatsoever will MJ Biotech. Inc. and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

SOURCE: MJ Biotech, Inc.